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Abstract
Hepatitis B virus (HBV) infection is of global importance with over 2 billion people
exposed to the virus during their lifetime and at risk of progressive liver disease, cir-
rhosis and hepatocellular carcinoma. HBV is a member of the Hepadnaviridae family
that replicates via episomal copies of a covalently closed circular DNA (cccDNA)
genome. The chromatinization of this small viral genome, with overlapping open
reading frames and regulatory elements, suggests an important role for epigenetic
pathways to regulate viral transcription. The chromatin-organising transcriptional
insulator protein, CCCTC-binding factor (CTCF), has been reported to regulate tran-
scription in a diverse range of viruses. We identified two conserved CTCF binding
sites in the HBV genome within enhancer I and chromatin immunoprecipitation
(ChIP) analysis demonstrated an enrichment of CTCF binding to integrated or epi-
somal copies of the viral genome. siRNA knock-down of CTCF results in a significant
increase in pre-genomic RNA levels in de novo infected HepG2 cells and those
supporting episomal HBV DNA replication. Furthermore, mutation of these sites in
HBV DNA minicircles abrogated CTCF binding and increased pre-genomic RNA
levels, providing evidence of a direct role for CTCF in repressing HBV transcription.
K E YWORD S
CTCF, epigenetics, HBV, transcription insulation, transcription regulation
1 | INTRODUCTION
Hepatitis B virus (HBV) infection is one of the world's unconquered
infections with an estimated 2 billion people exposed to the virus in
their lifetime. HBV replicates in hepatocytes, and chronic infection
can result in progressive liver disease, cirrhosis and hepatocellular car-
cinoma. HBV is a member of the Hepadnaviridae family and is classi-
fied into eight genotypes, A-H (McNaughton et al., 2019), that can
associate with different clinical outcomes and treatment responses
(Kao, Chen, Lai, & Chen, 2000). The HBV genome is a small, partially
double-stranded relaxed circular DNA (rcDNA) of approximately
3.2 Kb. Following HBV entry into hepatocytes via the liver-specific
bile-acid transporter, sodium taurocholate co-transporting polypeptide
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(NTCP) (Ni et al., 2014), rcDNA is released into the nucleus and is
repaired by host DNA repair pathways to generate covalently closed
circular DNA (cccDNA). This cccDNA persists in the nucleus as a long-
lived nucleosome-associated minichromosome (Lythgoe, Lumley,
McKeating, & Mathews, 2020) and is the transcriptional template for
all viral RNAs (Hong, Kim, & Guo, 2017).
The HBV genome is transcribed by the host RNA polymerase II
(RNA pol II) complex from four promoters (basal core promoter, BCP,
Sp1, Sp2 and Xp) (Hong et al., 2017) that results in six major viral
RNAs of increasing length with heterogeneous 50 ends and a common
polyadenylation signal (Stadelmayer et al., 2020). These RNAs include:
pre-core (preC) that encodes e antigen (HBeAg); pre-genomic (pgRNA)
that is translated to yield core protein (HBcAg) and polymerase; preS1,
preS2 and S RNAs encoding the surface envelope glycoproteins and
X transcript for the multi-functional x protein (HBx). Two viral
enhancers regulate viral transcription: Enhancer I (EnhI) is located
upstream of and partially overlaps the X promoter (Xp) and directs
BCP activity (Hu & Siddiqui, 1991), which stimulates the production
of both preC and pgRNAs. Enhancer II (EnhII) overlaps a large portion
of BCP and stimulates activity of the distal Sp1 and Sp2 promoters, as
well as the BCP and Xp (Yuh & Ting, 1990). The BCP encodes a nega-
tive regulatory element (NRE) that overlaps with Enh II (Sun
et al., 2001) and has been reported to repress promoter activity.
Encapsidated pgRNA is reverse-transcribed by the viral polymerase to
generate new DNA genomes that can be re-imported to the nucleus
to maintain the cccDNA pool or are enveloped and secreted as infec-
tious particles (Urban, Schulze, Dandri, & Petersen, 2010), highlighting
an essential role for the BCP in regulating viral replication.
HBV cccDNA is assembled into nucleosomes by cellular histones
to form episomal chromatin (Levrero et al., 2009). The viral DNA is
enriched with active epigenetic histone modifications including
trimethylation of lysine 4 (H3K4Me3) and acetylation of lysine 27 on
histone 3 (H3K27Ac) but devoid of repressive marks, such as
trimethylation of lysine 27 on histone 3 (H3K27Me3) (Flecken
et al., 2019; Tropberger et al., 2015). The overlap of active histone
marks with RNA pol II occupancy suggests that viral transcription is
regulated by epigenetic modification. In support of this, treating de
novo infected primary human hepatocytes with inhibitors of the his-
tone acetyltransferase p300/CBP reduces HBV RNA levels
(Tropberger et al., 2015). Although the mechanisms underlying the
epigenetic regulation of HBV cccDNA are not fully understood, sev-
eral epigenetic modifiers are recruited to HBV cccDNA by HBx. As
such, HBx behaves as a transcriptional regulator of both viral and cel-
lular promoters (Guerrieri et al., 2017), and although HBx cannot bind
to DNA directly, it can associate with components of the basal tran-
scription machinery, transcription factors and transcriptional co-
activators (Tang, Oishi, Kaneko, & Murakami, 2006). HBx coordinates
the recruitment of the CBP/p300 and PCAF histone acetyl transfer-
ases (HAT) to cccDNA while facilitating the exclusion of histone
deacetylases (HDACs) HDAC1 and Sirtuin 1 (Sirt1), resulting in hyper-
acetylation of cccDNA (Belloni et al., 2009; Chong et al., 2020). HBV
transcription is dependent on an array of ubiquitous and liver-specific
cellular transcription factors, including the liver-specific hepatocyte
nuclear factors, 1 and 4 (HNF-1/4), and ubiquitously expressed
octamer-binding protein 1 and specificity protein 1 (reviewed in
Oropeza et al., 2020; Turton, Meier-Stephenson, Badmalia, Coffin, &
Patel, 2020).
The genomes of metazoans are organised into megabase-sized
regions termed topologically associated domains (TADs) that provide
regulatory segmentation required for appropriate gene expression and
replication. TADs are separated by regions enriched in binding sites of
the ubiquitously expressed CCCTC-binding factor (CTCF), which sta-
bilises chromatin loops by anchoring cohesin rings at the base of the
loops (Rowley & Corces, 2018). Such spatial organisation can create
epigenetic boundaries that separate transcriptionally active and inac-
tive chromatin domains and control cis-regulatory elements, such as
transcriptional enhancers. CTCF binds to tens of thousands of either
ubiquitous or cell type specific consensus binding sites within the
human genome, regulating both tissue-specific and developmental
changes in gene expression (Chen, Tian, Shu, Bo, & Wang, 2012).
The occupancy of specific CTCF binding sites is dictated by chro-
matin accessibility and local epigenetic status (Kumar &
Bucher, 2016). In addition to the organisation of chromatin domains,
CTCF can function as a transcriptional repressor, or activator, by
direct association with promoter proximal elements. CTCF was shown
to act as a transcriptional repressor of the c-myc oncogene by creating
a roadblock to RNA pol II (Filippova et al., 1996). Conversely, CTCF
can physically associate with transcriptional regulators, such as the
general transcription factor, TFII-I, to promote recruitment of the
cyclin-dependent kinase 8, resulting in stimulation of RNA pol II activ-
ity (Pena-Hernandez et al., 2015). CTCF regulates the transcription
(up or down) of evolutionarily distinct DNA viruses (Pentland &
Parish, 2015) including: Kaposi sarcoma-associated herpesvirus;
Epstein–Barr virus and herpes simplex virus (Chen et al., 2014; Kang,
Wiedmer, Yuan, Robertson, & Lieberman, 2011; Lang et al., 2017;
Washington, Musarrat, Ertel, Backes, & Neumann, 2018). We have
demonstrated that CTCF recruitment to the human papillomavirus
(HPV) genome negatively regulates early promoter usage via host cell
differentiation-specific stabilisation of an epigenetically repressed
chromatin loop (Paris et al., 2015; Pentland et al., 2018). However, a
role in HBV transcription regulation has not yet been reported, herein
we show that CTCF binds HBV DNA and acts as a repressor of viral
transcription.
2 | RESULTS
2.1 | CTCF binds HBV DNA at conserved sites
within enhancer elements
To investigate a role for CTCF in the HBV life cycle, we first assessed
whether the viral genome encodes any CTCF binding sites, using an
open access database (http://insulatordb.uthsc.edu/), to identify puta-
tive binding sites. Screening >7,000 HBV sequences available in the
HBV database (Hayer et al., 2013) identified two CTCF binding sites
(BS) between nucleotides 1194–1209 in EnhI (CTCF BS1) and
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1275–1291 in the Xp (CTCF BS2). Importantly, these binding sites are
conserved among all HBV genotypes (Figure 1a). The Hepadnaviridae
family includes a number of related viruses that infect other species,
including birds, mammals, fish, reptiles and amphibians. Inspection of
reference sequences from distinct Hepadnaviridae showed that both
consensus CTCF binding sites are conserved in viruses infecting pri-
mates and the majority of mammals and bats but are absent from
viruses infecting birds, fish or amphibians, demonstrating evolutionary
conservation of both CTCF binding sites (Figure 1b).
To assess whether these putative motifs can bind CTCF, we
selected two independent lines, HepG2.2.15 (Sells et al., 1987) and
HepAD38 (Ladner et al., 1997), that carry integrated copies of HBV
genomes, maintain cccDNA and generate infectious virus. We isolated
chromatin from nuclear fractions to limit contamination of cytoplas-
mic rcDNA and performed anti-CTCF chromatin immunoprecipitation
(ChIP) followed by quantitative PCR (ChIP-qPCR). Primers were
selected to amplify 100–200 base pair regions of the viral genome to
provisionally identify CTCF binding sites. We show low-level CTCF
binding above the control IgG across the viral DNA with a significant
enrichment in the Xp in both cell lines (Figure 2a), consistent with our
motif scanning results. These data are in line with earlier reports for
CTCF binding cellular target genes (Zhang et al., 2017). Analysing his-
tone modifications of HBV chromatin purified from HepG2.2.15 cells
showed minimal evidence for the repressive H3K27Me3, which is in
agreement with previous reports (Flecken et al., 2019; Tropberger
et al., 2015) (Figure 2b). In contrast, ChIP for histone marks associat-
ing with active transcription, including H4Ac and H3K4Me3, identified
these epigenetic marks throughout the viral genome, with an enrich-
ment in the BCP and Xp regions (Figure 2b).
Since both HepG2.2.15 and HepAD38 cell lines carry integrated
viral genomes and cccDNA, we are unable to discriminate CTCF bind-
ing between these forms of viral DNA. We studied HepG2 cells
expressing an episomal copy of HBV DNA (HepG2-HBV-Epi) (Lucifora
et al., 2014) to evaluate whether CTCF can bind episomal non-
integrated copies of HBV DNA. Our initial experiments assessed
whether our sonication protocol sheared HBV DNA by PCR amplifica-
tion using primers for viral targets of increasing length pre- and post-
sonication. While the unsheared chromatin yielded a series of PCR
products of increasing length, only amplicons below 238 base pairs
were detected in the sonicated material (Figure 2c). Amplicons over
353 base pairs were barely visible in the sonicated samples, demon-
strating effective shearing of episomal HBV genomes. ChIP of sheared
chromatin, isolated from HepG2-HBV-Epi nuclear extracts, showed
CTCF bound to the EnhI region (Figure 2d). We noted relatively lower
ChIP of viral DNA from the HepG2-HBV-Epi cells compared to
HepG2.2.15 or HepAD38 cells, which may reflect differences in the
epigenetic status of the viral DNA in these model systems. Our obser-
vation that CTCF binds EnhI, the major transcriptional regulatory ele-
ment of the BCP and Xp, suggests that CTCF regulates its activity.
2.2 | CTCF represses HBV enhancer I
To analyse the role of CTCF in regulating HBV enhancer activity, we
used promoter constructs encoding Firefly luciferase under the con-
trol of EnhI and Xp (nt 900-1358) or the BCP (nt 900-1859)
(Figure 3a) (Ko, Lee, Windisch, & Ryu, 2014). We silenced CTCF in
HepG2-NTCP using an siRNA Smartpool (Figure 3b) and transfected
the viral promoter plasmids along with a Renilla luciferase control plas-
mid and measured the activity after 72 hr. Transient knock-down of
CTCF protein significantly increased HBV EnhI activity (Figure 3c). To
assess whether the putative CTCF directly regulated EnhI, we intro-
duced silent mutations into the pEnhI-Luc to abrogate CTCF binding
(Schmidt et al., 2012), without altering the polymerase protein
sequence as this would adversely affect subsequent experiments with
intact HBV genomes (Figure 3a). Mutation of either CTCF BS1 (BS1m)
F IGURE 1 Identification of conserved CTCF binding sites in HBV
genomes and diverse Hepadnaviridae. (a) Conservation of CTCF BS
among 7,313 HBV sequences (HBVdb.fr). All sites, except where
indicated, are >98% conserved. (b) Neighbour-joining phylogenetic
tree of members of the Hepadnaviridae (adapted from McNaughton
et al., 2019). The green box shows viral genomes that encode both
CTCF BS1 and 2 (all human and old world primate viruses), whereas
the blue box shows viral genomes encoding only CTCF BS1 (new
world monkeys, woodchucks and all bats except the tent making bat)
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F IGURE 2 CTCF associates with HBV DNA and is enriched at viral Enhancer I and X promoter. (a) Association of CTCF with HBV DNA in
HepG2.2.15 and HepAD38 cells was analysed by ChIP-qPCR and presented as % Input recovery. Statistical significance shows comparison of
CTCF-specific ChIP with maximal recovery using IgG control (dotted line). (b) The distribution of histone modifications (H3K4Me3, H3K27Me3
and H4Ac) in HepG2.2.15 cells by ChIP-qPCR. (c) Chromatin shearing in HepG2-HBV-Epi cells was assessed by PCR of sonicated versus non-
sonicated chromatin. Amplicons were generated with a constant sense primer (anneals at nt 69) and anti-sense primers binding at increasing
distance from the sense primer (nt 159, 307, 422, 653 and 801). Amplification of HBV DNA was assessed by SyBr green staining of bands
separated by electrophoresis. (d) Association of CTCF was assessed by ChIP-qPCR. (A, B and D) Data shown are the mean ± SEM of three
technical repeats and are representative of three biological repetitions. p values were determined using a paired t test. *denotes p < .05,
**denotes p < .01, ***denotes p < .001. Annotation of HBV genome features, including open reading frames, enhancers and selected promoters, is
shown below the histograms
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or BS2 (BS2m) in isolation or in combination (BS1/2m) abrogated
the increase in EnhI activity after CTCF depletion (Figure 3c). Silenc-
ing CTCF protein showed a minimal effect on the BCP activity,
suggesting that CTCF represses EnhI but this effect may be blunted
in the presence of an NRE and overall reduced activity in the full
transcriptional reporter construct (Figure 3c). Together, these data
suggest that CTCF binds to both motifs within EnhI to directly
repress its activity.
2.3 | Silencing CTCF increases HBV preC/pgRNA
levels
To determine the effect of CTCF depletion on viral transcripts, we
selected to use the HepG2-HBV-Epi cells as we previously demon-
strated CTCF binding to the viral genome in these cells. We confirmed
effective knock-down of CTCF at the protein and RNA level 72 hr
post-siRNA transfection (Figure 4a). We observed a significant
increase in total HBV transcripts and preC/pgRNA levels after CTCF
depletion (Figure 4b,c). To determine whether the observed increase
in preC/pgRNA levels was due to an alteration of the HBV epigenome
after CTCF depletion, we measured H4Ac modification of viral DNA
as this was previously reported to associate with HBV transcription
(Pollicino et al., 2006). Silencing of CTCF in HepG2-HBV-Epi cells
increased H4Ac abundance within the viral enhancers, BCP Xp and
BCP, suggesting that CTCF regulates the epigenetic status of HBV
cccDNA (Figure 4d).
To extend our studies and to validate a role for CTCF in repre-
ssing viral transcription during a de novo infection, we silenced CTCF
in HBV infected HepG2-NTCP cells (Figure 5a). Efficient depletion of
CTCF was demonstrated by western blotting (Figure 5a), and viral
RNAs were analysed by RT-qPCR. In agreement with our earlier data
with HepG2-HBV-Epi cells, CTCF depletion in this de novo infection
model increased total transcripts and preC/pgRNA levels (Figure 5b,c).
We previously reported a qPCR technique to quantify the relative
abundance of HBV RNAs (D'Arienzo et al., 2019), and we used this
method to assess the effect of CTCF silencing on the pattern of viral
RNAs, showing no significant differences in the pattern of preS1,
preS2 and HBx RNAs (Figure 5d). These data support a model where
CTCF represses HBV cccDNA transcription, the major transcriptional
template in de novo infected HepG2-NTCP cells. Taken together, our
findings provide evidence that CTCF represses the BCP activity and
hence preC/pgRNA levels.
2.4 | Mutation of CTCF binding sites within HBV
enhancer I increases transcription
To demonstrate a direct role for CTCF binding to, and regulating,
cccDNA transcription, we utilised the HBV minicircle (mcHBV)
F IGURE 3 CTCF represses HBV Enhancer I activity. (a) Depiction of HBV genome regions cloned upstream of Firefly luciferase in
transcriptional reporter plasmids and mutagenesis strategy of CTCF BS1 and BS2 showing viral enhancers, Xp and BCP, and CTCF BS 1 (blue) and
CTCF BS 2 (green). (b) Western blot showing depletion of CTCF after siRNA transfection in pEnhI-Luc and pBCP-Luc transfected HepG2-NTCP
cells. (c) Firefly luciferase activity normalised to Renilla luciferase expression in HepG2-NTCP cells co-transfected with pGL3-basic, pEnhI-Luc or
pBCP-Luc and either scrambled (Scr) or CTCF-specific siRNA duplexes. Normalised luciferase activity in HepG2-NTCP cells transfected pEnhI-Luc
containing mutations in CTCF binding site 1 (BS1m) or 2 (BS2m) or a combination of both (BS1/2m). Data shown are the mean ± SEM of three
independent repetitions. p values were determined by the Sidak's ANOVA multiple comparisons test. ***denotes p < .001
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technology, as a model to study cccDNA transcription and replication
(Yan et al., 2017). We mutated CTCF BS1 and BS2 alone or in combi-
nation in the mcHBV as described in Figure 3a. HepG2-NTCP cells
were transfected with wild-type mcHBV (WT) or mutant mcHBV;
BS1m, BS2m or BS1/2m, and harvested 3 days after transfection
(Figure 6a). Analysis of CTCF binding by ChIP revealed that mutation
of BS1 or BS2 alone significantly reduced CTCF binding by over >75%
with the combined mutation resulting in an almost complete loss of
CTCF-mcHBV complexes (Figure 6b). qPCR analysis showed a signifi-
cant increase in preC/pgRNA levels when either or both of the CTCF
BS were mutated (Figure 6c). However, no differences were
observed in HBV mcDNA levels, confirming comparable transfection
efficiencies (Figure 6d). These data provide evidence of direct recruit-
ment of CTCF to HBV DNA and show a repressive role for CTCF in
regulating HBV transcription.
3 | DISCUSSION
In this study, we identified two CTCF-binding motifs within transcrip-
tion regulatory elements, EnhI and Xp, of the HBV genome. We dem-
onstrate CTCF binding to HBV DNA by ChIP-qPCR in the region of
these binding sites using various model systems that bear both inte-
grated genomes and a cccDNA pool, or cells exclusively expressing
F IGURE 4 CTCF represses preC/
pgRNA transcription from HBV cccDNA.
(a) HepG2-HBV-Epi cells were un-
transfected (UT) or transfected with
scrambled (Scr) or CTCF-specific siRNA
duplexes and incubated for 72 hr. CTCF
depletion was assessed by western
blotting and quantification in three
independent experiments shown. (b) Total
viral RNA and (c) preC/pgRNA levels were
quantified by qPCR as previously described
(D'Arienzo et al., 2019). Data are the
mean ± SD of two independent
experiments performed in triplicate.
p values were determined by the Kruskal–
Wallis ANOVA multiple group comparison.
(d) Enrichment of H4Ac marks was
assessed by ChIP-qPCR and shown as %
Input recovery. p values were determined
using a paired t test. *denotes p < .05,
**denotes p < .01, ***denotes p < .001
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episomal copies of viral DNA. Our sonication method sheared
cccDNA-like episomes and demonstrated CTCF binding to EnhI, albeit
slightly upstream of the peak enrichment of CTCF binding in the
integrant lines. This altered location of CTCF binding could reflect dif-
ferential usage of CTCF binding sites in the different model systems
or could reflect less efficient shearing of cccDNA-like molecules com-
pared to integrated HBV DNA. Nonetheless, our ChIP-qPCR experi-
ments allowed provisional mapping of CTCF binding sites that were
confirmed by mutagenesis studies using promoter reporter constructs
and mcHBV DNA. Importantly, these CTCF binding sites are con-
served among all HBV genotypes and across the wider Hepadnaviridae
family, consistent with an evolutionary conserved role in the replica-
tion of these viruses. Finally, we show a role for CTCF to repress HBV
transcription.
Using several complementary HBV replication models, we
show that siRNA depletion of CTCF and mutation of CTCF binding
sites significantly increased preC/pgRNA levels, consistent with a
role for CTCF in repressing viral transcription. To understand the
mechanism of CTCF action, we used transcriptional reporter assays
and found that silencing CTCF significantly increased EnhI activity.
Furthermore, mutating the CTCF BS within EnhI attenuated this
phenotype, confirming a direct role for CTCF in regulating EnhI.
However, analysis of the full BCP, containing both EnhI and EnhII,
revealed that the phenotype of CTCF silencing was lost. It is likely
that the attenuation of BCP activity after CTCF silencing is
explained by the dominant repressive effects of the NRE within
EnhII, highlighting the context-dependent activity of CTCF in regu-
lating HBV. However, increased activity of the BCP is observed
after CTCF silencing in cells containing the full viral episome, which
may reflect differential chromatinization and epigenetic modifica-
tion of the transcriptional reporters as compared to the full viral
episome. Alternatively, the transcriptional elements in isolation are
no longer subject to regulation by distal elements contained within
the intact episome. While the transcriptional reporters used in this
study provide a useful tool in the initial characterisation of CTCF
function in HBV EnhI modulation, the results obtained in the con-
text of a chromatinised viral episome may better reflect the role of
CTCF in the HBV infection cycle.
To confirm a direct role of CTCF in repressing HBV transcrip-
tion, we transfected HepG2-NTCP cells with mcHBV mutated in the
CTCF BSs. Although the extent to which we could mutate CTCF BS
was limited, to maintain the amino acid sequence of the polymerase,
we observed a significant reduction of CTCF binding to mcHBV, lac-
king either BS1 or BS2, or both sites mutated in combination. These
studies identify CTCF BSs within the viral genome and confirm
CTCF association with HBV DNA. Consistent with the increased
preC/pgRNA levels observed in two HBV replication model systems
after CTCF depletion, we observed a significant increase in preC/
pgRNA when CTCF BS1 was mutated. A similar increase in preC/
pgRNA was observed when CTCF BS2 was mutated, although this
did not reach statistical significance. While the mutation of both BS
showed a significant increase in preC/pgRNA abundance, suggesting
F IGURE 5 CTCF represses
HBV preC/pgRNA transcription
in de novo infected
HepG2-NTCP cells. (a) HBV
infected HepG2-NTCP were
transfected with scrambled (Scr)
or CTCF-specific siRNA duplexes
and cultured for 72 hr and CTCF
depletion assessed by western
blotting. (b) Total HBV transcript
abundance, (c) preC/pgRNA
levels and (d) the relative
proportion of individual HBV
transcripts were analysed by PCR
as previously described
(D'Arienzo et al., 2019). Data are
the mean ± SD of two
independent experiments
performed in triplicate. p values
were determined using the
Mann–Whitney U test (two group
comparisons). *denotes p < .05,
**denotes p < .01
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these sites do not function in a synergistic manner within this model
system.
Aberrant reverse transcription of pgRNA can generate double-
stranded linear DNA that can integrate into the host genome (Tu,
Budzinska, Shackel, & Urban, 2017). This integration step is not part
of the productive HBV life cycle and occurs at a low frequency (<1
copy per diploid host genome in infected tissues) (Podlaha
et al., 2019). Since integrated copies of HBV DNA generally lack a
functional basal core promoter and associated CTCF binding sites,
we would anticipate a minimal role for CTCF in directly regulating
integrant derived transcripts. HBV integration can cause host geno-
mic instability leading to tumour progression through tumour sup-
pressor gene inactivation and/or oncogene activation (Zhao
et al., 2016). Oncogenic integration events are thought to provide a
growth advantage to cells, inducing tumourigenesis. HBV integration
occurs at random sites, although a preference for integration within
regions of open chromatin has been reported (Furuta et al., 2018). It
will be interesting to determine whether integration of HBV DNA
into the host results in an alteration of local chromatin interactions
and host cell gene regulation by the insertion of a virally encoded
CTCF binding site(s), as reported for the human retrovirus, HTLV-1
(Melamed et al., 2018). Such genomic rearrangements could have an
impact on host cell gene expression and contribute to HBV-driven
carcinogenesis.
Analysing the epigenetic status of HBV DNA in HepG2.2.15 hep-
atoma cells revealed a lack of the repressive H3K27Me3 and enrich-
ment of epigenetic marks associated with active transcription in the
BCP and Xp regions, downstream of the CTCF binding sites. We
noted a similar enrichment of H4Ac in episomal DNA in HepG2-HBV-
Epi cells. These findings are consistent with previous reports studying
the epigenetic status of HBV cccDNA in various model systems and
liver biopsy samples (Flecken et al., 2019; Tropberger et al., 2015).
Silencing of CTCF resulted in an increase in H4Ac abundance in HBV
cccDNA, which associates with increased HBV preC/pgRNA levels.
CTCF has been reported to directly repress transcription via recruit-
ment of the Sin3/histone deacetylase compressor complex resulting
in reduced histone acetylation (Lutz et al., 2000) that may explain
these observations.
Taken together, these findings suggest that CTCF represses
HBV transcription by insulating the BCP from the upstream
enhancer element. EnhI is an important regulator of all HBV pro-
moters and is essential for viral transcription (Hu & Siddiqui, 1991).
In support of this, HBV-transgenic mice, lacking EnhI, are defective
in virion production (Guidotti, Matzke, Schaller, & Chisari, 1995).
The repression of EnhI by CTCF is likely to have a significant impact
on the virus life cycle and reduce particle genesis and may there-
fore limit cccDNA pools. To assess whether infection perturbs
CTCF expression, we analysed a publically available Affymetrix
microarray database from chronic HBV infected patients (Zhou
et al., 2017). We observed comparable CTCF transcript levels in
normal and chronic HBV infected samples (Figure S1) with no evi-
dence for HBV infection to perturb intra-hepatic CTCF transcript
levels.
Analysis of the genomic distribution of CTCF BS in the human
genome suggests a similar enhancer-blocking activity of CTCF as
numerous CTCF binding loci are situated between known transcrip-
tional enhancers and associated promoter elements (Xie
et al., 2007). Such enhancer-blocking activity has been extensively
characterised at imprinted loci, such as the insulin-like growth factor
2 (IGF2)/H19 locus and in development at the β-globin locus (Bell,
West, & Felsenfeld, 1999; Chung, Whiteley, & Felsenfeld, 1993).
CTCF regulates herpes simplex virus differential transcriptional
programmes during the lytic and latent phases of the viral life cycle
through its enhancer-blocking activity (Washington et al., 2018).
Our previous work with HPV showed that CTCF repressed tran-
scription by stabilising an epigenetically repressed chromatin loop
between the viral proximal enhancer and a distal CTCF binding site.
However, this repression was not associated with direct binding of
CTCF to the HPV enhancer, suggesting that HBV and HPV have
evolved fundamentally different mechanisms of CTCF-dependent
transcriptional repression.
F IGURE 6 Mutation of CTCF binding sites in HBV mcDNA
results in increased preC/pgRNA levels. (a) HepG2-NTCP cells were
transfected with wild type HBV mcDNA (WT) or mcDNA with CTCF
binding 1 (BS1m) or 2 (BS2m) or both sites mutated in combination
(BS1/2m). (b) Cells were harvested 72 hr post transfection and CTCF
binding analysed by ChIP-qPCR and presented as % of enrichment
relative to input chromatin (% input). (c) preC/pgRNA and levels were
quantified by qRT-PCR and normalised to cccDNA amount per cell
and (d) total HBV DNA levels were quantified by qRT-PCR and
normalised to cccDNA amount per cell to determine mcHBV
transfection efficiency. Data are the mean ± SEM of at least three
independent experiments. p values were determined using the
Kruskal–Wallis ANOVA multiple group comparison. *denotes p < .05,
**denotes p < .01
8 of 14 D'ARIENZO ET AL.
4 | EXPERIMENTAL PROCEDURES
4.1 | Cell lines and antibodies
HepG2.2.15 (Sells, Chen, & Acs, 1987), HepAD38 (Ladner
et al., 1997), HepG2-HBV-Epi (Lucifora et al., 2014) and
HepG2-NTCP cells were maintained in Dulbecco's Modified Eagles
Medium (DMEM, #31966) supplemented with 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 1 mM sodium pyruvate, 50 U/ml
penicillin/streptomycin and non-essential amino acids (all reagents
from Invitrogen, UK). All cells were maintained in a 5% CO2 atmo-
sphere at 37C. HepG2-HBV-Epi cells were kept at low passage to
limit HBV DNA integration. The following primary antibodies were
used: anti-CTCF (#61311), anti-H3K4Me3 (#39915), anti-H3K27Me3
(#39155) and anti-H4Ac (#39925) were all purchased from Active
Motif (UK) and anti-GAPDH (SC-32233) was purchased from
Santa Cruz.
4.2 | ChIP and quantitative PCR
HepG2.215, HepAD38 cells or HepG2-HBV-Epi cells were fixed with
1% formaldehyde (Sigma Aldrich) for 10 min at room temperature
before quenching with 125 mM glycine. The cells were washed with
ice cold PBS, containing EDTA-free protease inhibitors (Roche) and
5 mM sodium butyrate, and frozen at −80C. Pellets were re-
suspended in ChIP lysis buffer (Active Motif) supplemented with pro-
tease inhibitors and incubated on ice for 30 min. Cells were dounced
30 times using the tight pestle to release nuclei and centrifuged at
2500g for 10 min at 4C. The supernatant was removed and dis-
carded. Nuclei were re-suspended in shearing buffer (Active Motif)
pulse sonicated using a Sonics Vibra Cell CV18 sonicator fitted with a
micro-probe at 25% amplitude for 15 min on ice using 30 s on/off
cycles. Chromatin samples were cleared by centrifugation and stored
at −80C.
Sonication of HBV cccDNA was evaluated by conventional PCR
amplification of increasing amplicon size using a constant sense
primer and anti-sense primers described in Table 1. Phenol-
chloroform extracted DNA from HepG2-HBV-Epi cells before and
after sonication was quantified using a NanoDrop ND-1000 spectro-
photometer. PCR reactions included 100 ng DNA, MyTaq Red PCR
Mix (Bioline) and 200 nM sense/anti-sense primers and amplification
following 35 cycles of 95C, 15 s; 55C, 15 s; 72C, 30 s assessed by
agarose gel electrophoresis. Products were visualised using SyBr
Green Safe dye (Invitrogen).
For ChIP, sonicated lysates were clarified by centrifugation at
16,000g for 10 min and CTCF or histone complexes immuno-
precipitated with 5–8 μg antibody using a ChIP-IT® Express Chroma-
tin Immunoprecipitation kit, including Protein A magnetic beads as per
manufacturer's instructions (Active Motif, USA). The input and immu-
noprecipitated DNA were quantified by real-time PCR using a
Stratagene MX3500P PCR System. The values were calculated as %
recovery respective to input DNA signals. All oligonucleotide
sequences are listed in Table 1.
4.3 | siRNA transfection
Cells were trypsinized to reverse transfect with 25 nM of CTCF-
specific or scrambled TARGETplus Smartpool siRNAs (Horizon, USA)
using DharmaFECT4 (20% of amount recommended by the manufac-
turer's protocol; ThermoFisher). Cells with no siRNA (un-treated; UT)
were also assayed to assess lethality of CTCF depletion.
4.4 | SDS–PAGE and western blots
Cells were lysed in urea lysis buffer (8 M urea, 150 mM NaCl, 20 mM
Tris, pH 7.5, 0.5 M β-mercaptoethanol) supplemented with protease
inhibitor cocktail (Roche) and sonicated for 10 s at 20% amplitude
using a Sonics Vibra Cell sonicator fitted with a micro-probe. Follow-
ing quantification of protein concentration by Bradford assay, samples
were diluted in Lameli buffer before incubating at 95C for 5 min. Pro-
teins were separated on a 10% polyacrylamide gel and transferred to
PVDF membranes (Amersham). The membranes were blocked in
TBS-T, 5% skimmed milk, and proteins were detected using specific
primary (diluted at 1:1000) and HRP-secondary antibodies
(ThermoFisher, diluted at 1:10,000). Protein bands were detected
using Pierce SuperSignal West Pico chemiluminescent substrate kit
(Pierce) and images were collected using a Fusion FX Imaging system
(Peqlab).
4.5 | HBV transcription reporter assays
1 × 105 HepG2-NTCP cells were seeded in collagen-coated 24-well
plates. Immediately following cell seeding, transfection mixes were
added, containing 100 ng of either pGL3b-EnhI, pGL3b-BCP or
pGL3b-basic, 25 ng Renilla luciferase control plasmid (pCMV-
Renilla), 25 nM scrambled or CTCF-specific siRNA and 1.5 μl
Lipofectamine RNAiMAX™ (ThermoFisher) in 100 μl OptiMEM
(ThermoFisher). Cells were incubated at 37C, 5% CO2 for 72 hr
before being washed with PBS and 200 μl Passive Lysis buffer
(Promega) added to each well. Samples were incubated at RT for
30 min with gentle rocking. Lysates were cleared by centrifugation
and 20 μl of each added to a white 96-well microtiter plate. FireFly
and Renilla luciferase activity were detected using the Dual-Lucifer-
ase® Reporter Assay (Promega) using a GloMAX®-Multi Detection
system (Promega). 50 μl reagent added at a speed of 200 μl/s
followed by mixing and 2 s delay. Integration time was 10 s with
1 read/well for Firefly luciferase detection. The same protocol was
used for subsequent Renilla luciferase detection. Normalised lucifer-
ase activity was calculated by dividing Firefly luciferase activity by
Renilla luciferase activity.
D'ARIENZO ET AL. 9 of 14
4.6 | HBV de novo infection
Purified HBV was produced from HepAD38 cells as previously
reported (Ko et al., 2018). HepG2-NTCP cells were seeded on
collagen-coated plasticware and infected with HBV at an MOI of
250 genome equivalents per cell in the presence of 4% PEG 8,000.
Viral inoculum was removed 8 hr after infection, by extensive washing
with PBS, and cells were maintained in DMSO-free DMEM/10% FBS.
4.7 | RNA isolation for cDNA synthesis
Total cellular RNA was extracted using an RNeasy mini kit (Qiagen) fol-
lowing the manufacturer's protocol. To remove any residual HBV DNA,
the samples were treated with RNAse-free DNase I (14 Kunitz units/
rxn, Qiagen) for 30 min at RT. RNA concentration and quality were
assessed using a NanoDrop 1,000 spectrophotometer (ThermoFisher)
and 2,100 Bioanalyzer (Agilent). cDNA synthesis was performed with
0.25–1 μg of RNA in a 20 μl total reaction volume using a random
hexamer/oligo dT strand synthesis kit as per the manufacturer's instruc-
tions (10 min at 25C; 15 min at 42C; 15 min at 48C; SensiFast, Bio-
line). All oligonucleotide sequences are listed in Table 1.
4.8 | Quantitative PCR of HBV transcripts
All PCR reactions were performed using a SYBR green real-time PCR
protocol (qPCRBIO SyGreen, PCR Biosystems) in a Lightcycler 96™
TABLE 1 Detailing all primer
sequences used







CTCF BS1 CTGGATGGGGCTTGGTCATGCGC TTGGTGTTGCGTCAGCAAACACTTGG
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instrument (Roche). The amplification conditions were: 95C for 2 min
(enzyme activation), followed by 45 cycles of amplification (95C for
5 s; 60C for 30 s). A melting curve analysis was performed on the com-
pleted reactions to assess specificity and purity of the amplicons (95C
for 10 s; 60C for 60 s; followed by gradual heating from 60 to 97C at
1C/s). DNase-treated RNA samples that had not been reverse-
transcribed were amplified to verify the absence of residual DNA con-
tamination. All oligonucleotide sequences are listed in Table 1.
4.9 | HBV mcDNA purification and transfection
into cells
The plasmid, pMC-HBV, contains the 1.0 HBV genome (awy) and has
been previously described (Yan et al., 2017). CTCF BS1 and CTCF
BS2 were mutated by site-directed PCR mutagenesis using the
primers detailed in Table 1 and Prime Star Max (Takara) mutagenesis
kit following the manufacturer's protocols and confirmed by sequenc-
ing. ZYCY10P3S2T competent bacteria (System Bioscience) were then
transformed with the pMC-HBV (WT, BS1m, BS2m or BS1/2m) and a
single colony amplified in Terrific Broth overnight at 37C. Two vol-
umes of LB medium supplemented with 0.04 N NaOH and 0.02% L-
Arabinose were added to the culture and further incubated for 8 hr at
37C. Plasmid DNA was extracted using the Nucleobond Xtra Maxi
kit according to the manufacturer's protocol (Macherey-Nagel) and
digested with NdeI (New England Biolabs) for 2 hr at 37C and
plasmid-safe DNase (System Bioscience) overnight at 37C. After
purification, plasmid DNA was assessed by agarose gel electrophore-
sis to check for elimination of the parental plasmid. HepG2-NTCP
cells at 80–90% confluency were transfected with the pMC-HBV
plasmids using TransIT-2020 (Mirus) according to the manufacturer's
protocol in DMEM supplemented with 5% FBS, 1% Glutamax and 1%
sodium pyruvate. The following day, cells were washed once with
PBS and cultured for 72 hr in DMEM supplemented with 5% FBS, 1%
Glutamax, 1% sodium pyruvate and 1% penicillin/streptomycin.
4.10 | HBV nucleic acid quantification from
mcHBV-transfected cells
Total DNA was extracted using MasterPure™ Complete DNA Purifica-
tion Kit (Epicentre). Total RNA was extracted using ExtractAll
TRI-Reagent (Sigma Aldrich), precipitated in isopropanol, washed in
ethanol and re-suspended in RNase-free water. Extracted RNA was
digested with RNAse-free DNase I (Qiagen) and cDNA synthesised
using SuperScript III reverse transcriptase (Invitrogen). cccDNA was
quantified after ExoI + ExoIII endonuclease (Epicentre) digestion of
total extracted DNA for 2 hr at 37C, followed by 20 min inactivation
at 80C. Real-time qPCR for total HBV DNA and cccDNA was per-
formed using an Applied QuantStudio 7 machine (BioSystem) and
TaqMan Advanced Fast Master Mix. Total HBV DNA was quantified
using the TaqMan assay Pa03453406_s1; cccDNA specific primers
and probes were: forward 50-CCGTGTGCACTTCGCTTCA-30; reverse
50-GCACAGCTTGGAGGCTTGA-30 TaqMan probe [6FAM]
CATGGAGACCACCGTGAACGCCC[BBQ] (Testoni et al., 2019). Serial
dilutions of a plasmid containing an HBV monomer (pHBV-EcoRI)
served as quantification standard for total HBV DNA and cccDNA.
The number of cellular genomes was determined by using the β-globin
TaqMan assay Hs00758889_s1 (ThermoFisher). preC/pgRNA was
quantified using the following primers and probe: forward
50-GGAGTGTGGATTCGCACTCCT-30; reverse 50-AGATTGAGATCT
TCTGCGAC-30 and TaqMan probe [6FAM]AGGCAGGTCCCCTAGAA
GAAGAACTCC[BBQ] (Testoni et al., 2019). Relative amount was
normalised over the expression of housekeeping gene GUSB
(Hs99999908_m1).
4.11 | Chromatin immunoprecipitation from
infected HepG2-NTCP cells and mcHBV-transfected
cells
Seventy two hours after de novo infection or mcHBV transfection,
cells were washed twice with PBS and cross-linked with 1% formalde-
hyde for 10 minutes at 37C. After 5 min of quenching with 125 mM
glycine at 37C, cells were washed twice with PBS, centrifuged for
5 min at 300g and incubated with Nuclear Lysis Buffer (5 mM PIPES,
85 mM KCl, 0.5% NP-40) for 30 min on ice to isolate nuclei. The
lysate was then dounced 10 times and centrifuged for 5 min at 800g
at 4C. Nuclear membranes were then broken by two cycles of soni-
cation 30 s ON, 30 s OFF on a Bioruptor (Diagenode). Debris were
pelleted 10 min at 11,000g at 4C. The supernatant was diluted
10 times with RIPA buffer (10 mM Tris–HCl pH 7.5, 140 mM NaCl,
1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% SDS, 0.1% Na-
deoxycholate) supplemented with Complete Mini EDTA-free protease
inhibitor (Roche Diagnostics) and 1 mM PMSF and pre-cleared for
2 hr at 4C by adding magnetic Protein G Dynabeads (Life Technolo-
gies). Beads were discarded and 1 μg of anti-CTCF antibody
(Diagenode #C15410210) or isotype-matched negative control were
added to the chromatin. After an overnight incubation at 4C, mag-
netic Protein G Dynabeads and samples were incubated for 2 hr at
4C with agitation. Beads were washed five times with RIPA buffer,
once with TE buffer and re-suspended in Elution buffer (20 mM Tris–
HCl pH 7.5, 5 mM EDTA, 50 mM NaCl, 1% SDS, 50 μg/ml proteinase
K). Chromatin was reverse cross-linked by incubation at 68C for 2 hr
and purified by phenol:chloroform:isoamyl alcohol 25:24:1 (Life Tech-
nologies) extraction and ethanol precipitation. cccDNA was quantified
using the primers and probes listed above (Testoni et al., 2019).
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